The present invention provides compositions and methods for attaching tendon to bone. The present invention provides compositions and methods for treating rotator cuff injuries. In one embodiment, a method for treating rotator cuff injuries comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to at least one site of tendon reattachment on the humeral head.

The present invention relates to a microfluidic chip for attracting and destroying a specific biological element, said chip comprising: a reservoir (1) consisting of a matrix comprising a chemoattractant compound capable of attracting the biological element at least one network of microchannels (2) arranged between the reservoir (1) and the external environment (3) of the chip and allowing the chemoattractant compound to pass to said environment and the biological element present in said environment to pass to the reservoir (1) at least one electrode (4) arranged between the reservoir (1) and the network of microchannels (2) or at the same location as the network of microchannels (2), said electrode (4) being capable of generating an electric field so as to destroy the biological element during its passage to the reservoir (1).

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

Aspects of this disclosure relate generally to the use of biomaterials for the in vivo generation of CAR expressing cells. In some embodiments, the biomaterials comprise one or more of a cell recruitment composition, a viral vector, and/or a cell activation agent.

The present invention relates to a composition for skin whitening or wound treatment including liquid-type plasma, and more particularly, to a cosmetic composition for skin whitening and a pharmaceutical composition for treating and preventing skin pigmentation diseases which contain liquid-type plasma as an active ingredient. In addition, the present invention relates to a pharmaceutical composition for wound treatment, a quasi-drug composition, and a health functional food composition, which include liquid-type plasma and a growth factor as active ingredients, and a wound treatment method including a step of administering the composition to a subject or a step of applying the composition on the skin. The composition including liquid-type plasma and a growth factor of the present invention is capable of inducing the proliferation of fibroblasts, thereby exhibiting excellent wound treatment efficacy. Accordingly, the composition including liquid-type plasma and a growth factor of the present invention can be usefully applied to medicines including external preparations for wound treatment, etc.

The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.

Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products such as lysates related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions such as osteoarthritis.

The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1.sup.bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.

The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1.sup.bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.

The present invention provides a medium additive for promoting production of a paracrine factor in a cell, containing a compound represented by the following formula (I) or a salt thereof:

##STR00001##

wherein each symbol is as defined in the DESCRIPTION.